SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mangery3/6/2005 7:16:20 PM
   of 946
 
Carbo question.

In light of Dr. Biancos statement about the higher number of adverse effects with the xyotax arm, I was wondering if anyone here had an opinion or a link to a paper that could lend weight to carbos role in this. Granted carbo would be neccesary for treatment but I'm just trying to justify the xyotax number (higher than I expected), even given an assumed higher amount of cycles.

What reactions could 17 cycles of carbo over a 2 year period invoke.

Thanks
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News